Key facts
- This page summarizes Harlan Waksal's Form 4 filing for Lyra Therapeutics, Inc. (LYRA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 11 Dec 2024, 18:39.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Each Performance-based Restricted Stock unit ("PSU") represented a contingent right to receive one share of the Issuer's common stock.
Footnote F2
On March 21, 2024, the Reporting Person was granted a PSU for an aggregate of up to 385,000 shares of common stock under the Issuer's 2020 Incentive Award Plan (the "Agreement"). Under the terms of the Agreement, the underlying PSUs will become earned upon certain milestone events. On December 9, 2024, the Issuer determined that Milestone 1 of the PSU was achieved, resulting in 128,333 PSUs being earned. The earned PSUs will vest on January 31, 2028. The PSUs have no expiration date.